Clinical trial
Evaluation of SR 31747A Versus Placebo in Androgen-Independent Non Metastatic…
NCT00174863 · Sanofi, Industry · Completed
Key facts
| NCT number | NCT00174863 |
|---|---|
| Title | Evaluation of SR 31747A Versus Placebo in Androgen-Independent Non Metastatic Prostate Cancer |
| Official title | Evaluation of Two Doses of SR31747A (75 mg and 125 mg) in Non-Metastatic Androgen-Independent Prostate Cancer. Randomized, Double-Blind, Placebo Controlled Phase II Study |
| Acronym | ODYSSEY |
| Lead sponsor | Sanofi, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Prostatic Neoplasm |
| Intervention type | Drug |
| Interventions | SR31747A |
| Enrollment | 232 |
| Start date | Oct 1, 2003 |
| Primary completion | Aug 1, 2006 |
| Completion | Aug 1, 2006 |
| First posted | Sep 15, 2005 |
| Last update posted | Dec 23, 2008 |
| Countries | Australia, Belgium, Canada, Chile, Czechia, France, Italy, Mexico, Netherlands, Poland, Portugal, Spain and 1 more |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: